Home » Stocks » NGIO

NuGenerex Immuno-oncology, Inc. (NGIO)

NuGenerex Immuno-oncology will go public soon, but the exact IPO date is still unknown.
Stock Price: $8.50 - $9.50
Current IPO price range
Market Cap 952.70M
Revenue (ttm) n/a
Net Income (ttm) -4.63M
Shares Out 105.86M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

NuGenerex Immuno-oncology, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About NGIO

NuGenerex Immuno-oncology is focused on the regulation of the immune system to treat cancer and infectious diseases. To that end, we are developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key. With the Ii-Key vaccine technology, we are able to activate the immune system against target molecules, whether those targets are tumor associated antigens (TAAs) in cancer cells, or viral or bacterial proteins in infectious disease pathogens. Through our 20+ year history of research and developme... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Pending
CEO
Joseph Moscato
Employees
6
Stock Exchange
NASDAQ
Ticker Symbol
NGIO
Full Company Profile

Financial Performance

Financial Statements